Slide 1: ChromaDex August 2012 Investor Presentation
©) ChromaDex August 2012, Investor Presentation
Slide 2: Disclaimers
Disclaimers l2 ters gener etm oo Health Claims ©
Slide 3: Disclaimers (continued)
\ . a Disclaimers (continued) Is Forecasts ‘Allforecast are provided by management in his presentation and are based on information available ous at this bme {and management expects that intemal projections and expectations may change over me. n addin, the forecasts are tently on management's best e
Slide 4: ChromaDex at a Glance
es a + Founded 1999 by CEO Frank Jaksch + Headquarters: Irvine, CA + Analytical Laboratory: Boulder, CO ~ Acquired in April 2003 from NaPro BioTherapeutics = + Employees: Approximately 70 Irvine, CA Boulder, CO ‘+ Publcly-listed in 2008 (reverse merger) + Symbol (Exchange): CDXC (OTCBB) ChromaDex® A
Slide 5: ChromaDex financing history & warrants
ChromaDex® financing history & warrants Is Foon te = me meat on soe ven hee Son/stoetsesoca S/o oa inser | «asa ctareconmon cht iter = como ck saerasne spires | wir | nice ramon | jitsmedowec®, | cyersitceseed Dect | $075/stre | meni intone! tone Senee Warrants outstanding cmietincomecin | weidtedae
Slide 6: Management team
6 1 Fonied Crema 2 Pry CFO ate Pieper ey aerate, — oe ee ere fel entap era ini, Stat Engen ae 05 oma. vageae as aconing Unecty Seca ace fos eB See Ged ee coat Se ey, joaeonee ence ae Pens VP a er SPeesRe EAN Macaw ery space pa pee Ps Soe Genentech, Amgen, leadership rola |* Experience in process | ~
Slide 7: ChromaDex Serves Large and Growing Markets
ChromaDex Serves Large and Growing Markets Legacy Business Natural productfine J Analytical & chemisty- 9 Proprietary Prodi chemicals based servi ee | Cosmeceutical as
Slide 8: ChromaDex is at an Inflection Point
ChromaDex® is at an Inflection Point as it Commercializes its Pipeline of Proprietary Ee Products and Grows the Legacy Business ye Legacy Business ' Natural produc tne chemicals for QC and RED «= Anadfcal services testing for ident, potency, safely of dilary supplements & foodbeverage products Be —_
Slide 9: Partner with the Natural Products Industry
é : Partner with the Natural Products Industry Natural productfine chemicals ‘Analytical & chemistry-based services 1 Used for OA 8 RAD Testing for ierity, "3000+ Pancbased fne potency, salely chemicals * Mandactuing RED 1 800+ Botanicals * 04/0 & regusiony + Comprehensive colecton of constng thes i
Slide 10: The Legacy Business is Positioned for Growth
The Legacy Business is Positioned for Growth |10 t Increased consumer demand — natural products industry expected to reach $243B by 2015' ff Increased R&D by global blue-chip players — e.g. Pepsi Global Nutrition Group, Nestle Health Sciences tT Increased regulatory scrutiny — FDA implementation of
Slide 11: Legacy Business Brings Market Intelligence and First-mover Advantage
ee The Legacy Business Brings Market Intelligence, Giving ChromaDex® a First-mover Advantage in Commercializing Proprietary Products - ~ leadto soy whic a 7 # proude USDA WN + Unestes + Oise in ata + Te ‘Deveopment Pom? 1 poser sttons prods esa (dices ares deep, 2 Goreme «sere et tnd conmorclae ope
Slide 12: Internal Development Platform Identifies, Develops, Markets Novel Ingredients
“Tough the Legacy ‘Assess compounds for Business, dtcovernevel static ft. commercial compounds wi significant abi, ciical potertial heath potential This Internal Development Platform Identifies, Develops, & Markets Novel Ingredients for Health |12 ‘Commercialize Develop IP, cca & Fequatry pats, and
Slide 13: pTeroPure is the first product from the Development Platform
pTeroPure® is the first produ Development Platform pleréPure to come out of the = |13 pTeroPure' 1aDex branded pterostilbene + Pterostilbeneis phytoalexin (plant defense system) foundnaturally in blueberries + polyphenol with high bloavallabilty and a long half-life in the body as comparedto resvera
Slide 14: The Development Platform in action — pTeroPure case study
The Development Platform in action — |14 pTeroPure® case study 2003 2008 2012 Develop ‘Commercialize: 00s: Gommories 7007-2008: Gonos "009; Pamerswh Init Lamehes Dustin, wth USDA to peoude Seente & mare, ‘manutocuerto achieve | areaktvough etary suppiemert Felerence sandarésfor aseesometot commercia
Slide 15: Partnered with an industry leader for pTeroPure
ChromaDex has partnered with an industry leader 15 to capitalize on the market for pTeroPure® + Global ingredient and micronutrient premix company + Will serve as exclusive distributor for pTeroPure® in North America to the food, beverage and dietary supplementindustries + Broad distribution will en
Slide 16: pTeroPure Highlights
pTeroPure® Highlights |16 plersPuré Clinical rial completeat the University of Mississippi + Double-blind, andomizad, placebo-controlled, IRB-reviewed + Endpoints: cholesterol levels, trig cerides & blood pressure; oxidative stress markers, safety + 80 patients, 4 arms. Eight-week duration of treatm
Slide 17: pTeroPure Potential in Skin Care markets
pTeroPure® also has Significant Potential in Skin \a7 Care markets ‘Selence Overdew “Tne oint patents UC vine + Reseach demontteshe ality» __‘Persitene shown fore activate UBT ad nil pro-otarmator marr Ske COX2 inhib skin damage & aging effects SEhant oc + Upp smhrereest ptrty pen roe stam * Peresti
Slide 18: Proprietary Products at Various Stages of Development
ChromaDex*’s Proprietary Products are at Various | ., Stages of Development, Led by pTeroPure® eveeo “sass GES Y Ya 0 0 00 0 [Next-generation products for multiple applications are in development } ©
Slide 19: Anthocyanins — Next Product to Market
Anthocyanins — ChromaDex®’s Next Product to iia Market overview + Aathocyanins are compounds responsibie fo the deep purple color in boris, Towers, black ice and cher botanicals + Specie anttocyanins have been studed more extensively and have shown promising heath benefits ~e.9, eyanidin-3.glucoside
Slide 20: Nicotinamide Riboside — In Development
- es >@Nicotinamide Riboside — In Development |20 oF ove ° esr Rian ey acing sy td an sto wet ie Se i a se up ‘compound that enables cells to convert fuel to energy. Minn + NR has potential to bea next-generation Niacin (Vitamin B9) and add tothe portion ‘of Buvtamin ingrecents on the market foe ine
Slide 21: pTeroPure in retail brand BluScience
pTeroPure® is the key ingredient found in : Ja ChromaDex's retail brand, Bl Sciencé & s BluScienceé giascience ™ BioScience BluScience ® Bioscience $s Capsules and ora-dissolving melts 5 SKUs ~ anti-aging, heert-health, weight management, focus & energy melt, cognitive function Available at 7500 Wal
Slide 22: ChromaDex In Summary
an ChromaDex® In Summary lz2 * First proprietary product pTeroPure® pterostilbene + ProC3G™ & AnthoPure"™ Anthocyanins Propristary _« Nicotinamide Riboside(NR) nl rsa mr = awactonereay teats SRM ocsecte saa sams ereery ome ee La alec anak + Provides QA & research supportto industry, ees necesret ce
Slide 23: Contact Information
Contact Information ‘ChromaDex, ne. 0008 Muirlands Blvd, Suite G Irvine, CA 92618 Phone: +1-049-419.0288 Fax: +1-949-419-0294 wuw.chromadex.com Investor Relations 23 Bob Prag, President The Del Mar Consulting Group, Ine. Phone: 858,784,950 boprag@delmarconsulting.com ‘Scott Wilfong, President Alex P
Slide 24: Shareholder Summary
Shareholder Summary Shareholder Number of Shares onan Dr. Phillip Frost 15,252,937 1647% (Opko Health, In. 1933,333 198% Frank L Jaksch Jr 7,993,320 8.63% Barry Honig 7,731,316 8.35% Michael Brauser 4.459.924 431% Otis Deis and aa oa SUBTOTAL 38,260,044 41.30% | 24